Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-fat-fed rats: Implications for Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 4, 2016, Pages 511-517

  Rodriguez Perdigon, Manuel ^a   Solas, Maite ^a,b   Moreno Aliaga, Maria Jesús ^a,b   Ramirez, Maria Javier ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

Author keywords

Cognitive deficits; High fat diet; Insulin; Ketone bodies; VGlut1

Indexed keywords

GLUTAMIC ACID; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; KETONE BODY; PROTEIN KINASE B; THIOCTIC ACID; VESICULAR GLUTAMATE TRANSPORTER 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; HIPPOCAMPUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KETOACIDOSIS; LIPID DIET; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

EID: 84958191290     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.01.004     Document Type: Article

References (53)

1. Barbagallo M., Dominguez L.J. Type 2 diabetes mellitus and Alzheimer's disease. World J. Diabetes 2014, 5:889-893.
2. Caselli R.J., Chen K., Lee W., Alexander G.E., Reiman E.M. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch. Neurol. 2008, 65:1231-1236.
3. Mosconi L., Mistur R., Switalski R., Brys M., Glodzik L., Rich K., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72:513-520.
4. Langbaum J.B.S., Chen K., Caselli R.J., Lee W., Reschke C., Bandy D., Alexander G.E., Burns C.M., Kaszniak A.W., Reeder S.A., Corneveaux J.J., Allen A.N., Pruzin J., Huentelman M.J., Fleisher A.S., Reiman E.M. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch. Neurol. 2010, 67:462-468.
5. Hoyer S., Nitsch R., Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J. Neural Transm. Park. Dis. Dement. Sect. 1991, 3:1-14.
6. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signalling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
7. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-resistance, IRS-dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
8. Ma L., Wang J., Li Y. Insulin resistance and cognitive dysfunction. Clin. Chim. Acta. Int. J. Clin. Chem. 2015, 444:18-23.
9. Hokama M., Oka S., Leon J., Ninomiya T., Honda H., Sasaki K., Iwaki T., Ohara T., Sasaki T., LaFerla F.M., Kiyohara Y., Nakabeppu Y. Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. Cereb. Cortex N. Y. N. 2014, 24:2476-2488.
10. Zheng W.H., Quirion R. Glutamate acting on N-methyl-d-aspartate receptors attenuates insulin-like growth factor-receptor tyrosine phosphorylation and its survival signalling properties in rat hippocampal neurons. J. Biol. Chem. 2009, 284:855-861.
11. McEntee W.J., Crook T.H. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology 1993, 111:391-401.
12. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
13. Francis P.T., Ramírez M.J., Lai M.K. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010, 59:221-229.
14. Fremeau R.T., Kam K., Qureshi T., Johnson J., Copenhagen D.R., Storm-Mathisen J., Chaudhry F.A., Nicoll R.A., Edwards R.H. Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 2004, 304:1815-1819.
15. Wojcik S.M., Rhee J.S., Herzog E., Sigler A., Jahn R., Takamori S., Brose N., Rosenmund C. An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7158-7163.
16. Mitew S., Kirkcaldie M.T.K., Dickson T.C., Vickers J.C. Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiol. Aging 2013, 34:2341-2351.
17. Kashani A., Lepicard E., Poirel O., Videau C., David J.P., Fallet-Bianco C., Simon A., Delacourte A., Giros B., Epelbaum J., Betancur C., El Mestikawy S. Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol. Aging 2008, 29:1619-1630.
18. Juge N., Gray J.A., Omote H., Miyaji T., Inoue T., Hara C., Uneyama H., Edwards R.H., Nicoll R.A., Moriyama Y. Metabolic control of vesicular glutamate transport and release. Neuron 2010, 68:99-112.
19. Yao J., Irwin R.W., Zhao L., Nilsen J., Hamilton R.T., Brinton R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14670-14675.
20. Fernández-Galilea M., Pérez-Matute P., Prieto-Hontoria P.L., Houssier M., Burrell M.A., Langin D., Martínez J.A., Moreno-Aliaga M.J. α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects. Biochim. Biophys. Acta 2015, 1851:273-281.
21. Kim M.S., Park J.Y., Namkoong C., Jang P.G., Ryu J.W., Song H.S., Yun J.Y., Namgoong I.S., Ha J., Park I.S., Lee I.K., Viollet B., Youn J.H., Lee H.K., Lee K.U. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 2004, 10:727-733.
22. Prieto-Hontoria P.L., Pérez-Matute P., Fernández-Galilea M., Alfredo M.J., Moreno-Aliaga M.J. Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low- and high-fat-fed rats. Eur. J. Nutr. 2013, 52:779-787.
23. Valdecantos M.P., Pérez-Matute P., González-Muniesa P., Prieto-Hontoria P.L., Moreno-Aliaga M.J., Martínez J.A. Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Obesity 2012, 20:1974-1983.
24. Bengoetxea X., Rodriguez-Perdigon M., Ramirez M.J. Object recognition test for studying cognitive impairments in animal models of Alzheimer's disease. Front. Biosci. Sch. Ed. 2015, 7:10-29.
25. Flanagan A.M., Brown J.L., Santiago C.A., Aad P.Y., Spicer L.J., Spicer M.T. High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J. Nutr. Biochem. 2008, 19:505-513.
26. Ribot J., Rodríguez A.M., Rodríguez E., Palou A. Adiponectin and resistin response in the onset of obesity in male and female rats. Obesity 2008, 16:723-730.
27. Norton S., Matthews F.E., Barnes D.E., Yaffe K., Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014, 13:788-794.
28. De la Monte S.M., Wands J.R. Alzheimer's disease is type 3 diabetes-evidence reviewed. J. Diabetes Sci. Technol. 2008, 2:1101-1113.
29. White M.F. IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes Obes. Metab. 2014, 16(Suppl. 1):4-15.
30. McNay E.C., Recknagel A.K. Brain insulin signalling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol. Learn. Mem. 2011, 96:432-442.
31. Moreno-Aliaga M.J., Pérez-Echarri N., Marcos-Gómez B., Larequi E., Gil-Bea F.J., Viollet B., Gimenez I., Martínez J.A., Prieto J., Bustos M. Cardiotrophin-is a key regulator of glucose and lipid metabolism. Cell Metab. 2011, 14:242-253.
32. Arnold S.E., Lucki I., Brookshire B.R., Carlson G.C., Browne C.A., Kazi H., Bang S., Choi B.R., Chen Y., McMullen M.F., Kim S.F. High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behaviour in mice. Neurobiol. Dis. 2014, 67:79-87.
33. Valdecantos M.P., Pérez-Matute P., Prieto-Hontoria P.L., Sánchez-Campayo E., Moreno-Aliaga M.J., Martínez J.A. Erythrocyte antioxidant defenses as a potential biomarker of liver mitochondrial status in different oxidative conditions. Biomarkers 2011, 16:670-678.
34. Castro G., M.F.C.A., L.W., P.G.Q., C.K.K., M.J.S., P.O.P. Diet-induced obesity induces endoplasmic reticulum stress and insulin resistance in the amygdala of rats. FEBS Open Bio 2013, 3:443-449.
35. Pessin J.E., Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 2000, 106:165-169.
36. Liu Y., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 2011, 225:54-62.
37. Greenwood C.E., Winocur G. High-fat diets, insulin resistance and declining cognitive function. Neurobiol. Aging 2005, 26(Suppl. 1):42-45.
38. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
39. Wang D., Yan J., Chen J., Wu W., Zhu X., Wang Y. Naringin improves neuronal insulin signalling, brain mitochondrial function, and cognitive function in high-fat diet-induced obese mice. Cell. Mol. Neurobiol. 2015, 35:1061-1071.
40. Petrov D., Pedrós I., Artiach G., Sureda F.X., Barroso E., Pallàs M., Casadesús G., Beas-Zarate C., Carro E., Ferrer I., Vazquez-Carrera M., Folch J., Camins A. High-fat diet-induced deregulation of hippocampal insulin signalling and mitochondrial homeostasis deficiencies contribute to Alzheimer disease pathology in rodents. Biochim. Biophys. Acta 2015, 1852:1687-1699.
41. De la Monte S.M., Wands J.R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis. 2006, 9:167-181.
42. Soscia S.J., Tong M., Xu X.J., Cohen A.C., Chu J., Wands J.R., de la Monte S.M. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell. Mol. Life Sci. 2006, 63:2039-2056.
43. Yao J., Rettberg J.R., Klosinski L.P., Cadenas E., Brinton R.D. Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol. Asp. Med. 2011, 32:247-257.
44. Vidali S., Aminzadeh S., Lambert B., Rutherford T., Sperl W., Kofler B., Feichtinger R.G. Mitochondria: the ketogenic diet-metabolism-based therapy. Int. J. Biochem. Cell Biol. 2015, 63:55-59.
45. Kanoski S.E., Zhang Y., Zheng W., Davidson T.L. The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat. J. Alzheimers Dis. 2010, 21:207-219.
46. Ikemoto A., Bole D.G., Ueda T. Glycolysis and glutamate accumulation into synaptic vesicles. Role of glyceraldehyde phosphate dehydrogenase and 3-phosphoglycerate kinase. J. Biol. Chem. 2003, 278:5929-5940.
47. Kirvell S.L., Esiri M., Francis P.T. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J. Neurochem. 2006, 98:939-950.
48. Lund T.M., Risa O., Sonnewald U., Schousboe A., Waagepetersen H.S. Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons. J. Neurochem. 2009, 110:80-91.
49. Lund T.M., Ploug K.B., Iversen A., Jensen A.A., Jansen-Olesen I. The metabolic impact of β-hydroxybutyrate on neurotransmission: reduced glycolysis mediates changes in calcium responses and KATP channel receptor sensitivity. J. Neurochem. 2014, 10.1111/jnc.12975.
50. Padmalayam I., Hasham S., Saxena U., Pillarisetti S. Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes 2009, 58:600-608.
51. Sancheti H., Kanamori K., Patil I., Díaz B.R., Ross B.D., Cadenas E. Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study. J. Cereb. Blood Flow Metab. 2014, 34:288-296.
52. Kirvell S.L., Elliott M.S., Kalaria R.N., Hortobágyi T., Ballard C.G., Francis P.T. Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study. Neurology 2010, 75:1803-1809.
53. Hertz L., Chen Y., Waagepetersen H.S. Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, β-amyloid toxicity, and astrocyte function. J. Neurochem. 2015, 10.1111/jnc.13107.